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INTRODUCTION
Breast cancer is the most commonly diagnosed cancer in 
women worldwide, as well as among Iranian women [1]. 
Common cancer therapies have several adverse effects. Hence, 
immunotherapy, which improves the patient’s own immune 
response, has been developed as an alternative to the tradi-
tional approaches [2]. Immunotherapy has the ability to attack 
microscopic disease and control metastasis, especially to loca-
tions that are surgically inaccessible. Reducing the side effects 
that are inevitable with radiation and chemotherapy as well as 
inducing long term control by suppressing the recurrence of 
tumors are some of the advantages of immunotherapy [3].
In order to obtain efficient clinical results from immuno-
therapy, the most effective immunotherapy agents should be 
combined with proper delivery strategies. Microorganism 
based delivery systems are one of the biological approaches. 
These systems are categorized into viral, bacterial, yeast, 
and parasite-based delivery systems [4]. In recent studies, 
nonpathogenic parasites including Leishmania tarentolae, 
Toxoplasma gondii, and Trypanosoma cruzi have been used as 
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Purpose: Immunotherapy is one of the treatment strategies for 
breast cancer, the most common cancer in women worldwide. 
In this approach, the patient’s immune system is stimulated to 
attack microscopic tumors and control metastasis. Here, we 
used interferon γ-induced protein 10 (IP-10), which induces and 
strengthens antitumor immunity, as an immunotherapeutic 
agent. We employed Leishmania tarentolae, a nonpathogenic 
lizard parasite that lacks the ability to persist in mammalian mac-
rophages, was used as a live delivery system for carrying the 
immunotherapeutic agent. It has been already shown that argi-
nase activity, and consequently, polyamine production, are as-
sociated with tumor progression. Methods: A live delivery system 
was constructed by stable transfection of pLEXSY plasmid con-
taining the IP-10-enhanced green fluorescent protein (IP-10-
egfp) fusion gene into L. tarentolae. Then, the presence of the 
IP-10-egfp gene and the accurate integration location into the 
parasite genome were confirmed. The therapeutic efficacy of IP-
10 delivered via L. tarentolae and recombinant pcDNA-(IP-
10-egfp) plasmid was compared by determining the arginase 
activity in a mouse 4T1 breast cancer model. Results: The pcDNA-
(IP-10-egfp) group showed a significant reduction in tumor 
weight and growth. Histological evaluation also revealed that 
only this group demonstrated inhibition of metastasis to the lung 
tissue. The arginase activity in the tissue of the pcDNA-(IP-
10-egfp) mice significantly decreased in comparison with that in 
normal mice. No significant difference was observed in arginase 
activity in the sera of mice receiving other therapeutic strategies. 
Conclusion: Our data indicates that IP-10 immunotherapy is a 
promising strategy for breast cancer treatment, as shown in the 
4T1-implanted BALB/c mouse model. However, the L. tarentolae-
(IP-10-EGFP) live delivery system requires dose modifications to 
achieve efficacy in the applied regimen (six injections in 3 
weeks). Our results indicate that the arginase assay could be a 
good biomarker to differentiate tumoral tissues from the normal 
ones.
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novel biological delivery systems for expression of heterolo-
gous genes [5]. In this study, L. tarentolae, a lizard parasite 
which is not pathogenic in humans and lacks the ability to 
persist long-term in mammalian macrophages [6], was used 
as a live delivery system for immunotherapy. L. tarentolae has 
the ability to induce T-cell proliferation and interferon γ 
(IFN-γ) production, subsequently eliciting a Th1 immune re-
sponse [5]. Our group has previously shown that early ex-
pressed number 7 protein human papillomavirus before 
(HPV)-EGFP (E7-EGFP) expressing recombinant L. tarentolae 
induces a strong Th1 immune response in the tumor cell line 
tissue culture number one (TC-1) inoculated mice as HPV 
model [7]. 
Arginase is a key enzyme in the hepatic urea cycle, which 
catalyzes L-arginine to urea and L-ornithine. Recently, many 
researchers have shown a crucial role for arginase in tumor 
immunobiology [8,9] and emphasized its potential role in the 
promotion of tumor growth via polyamine synthesis or 
downregulation of nitric oxide (NO)-mediated tumor cyto-
toxicity. It has also been suggested that arginase plays a role in 
the immunosuppressive function of tumor-associated my-
eloid-derived suppressor cell (MDSC). MDSCs constitutively 
express arginase and therefore, deplete L-arginine. Conse-
quently, T cell immune functions are suppressed. As arginase 
activity has been found to be elevated in many different can-
cers including breast, prostate, gastric, colorectal, and hepato-
cellular carcinoma, it can be used as a new prognostic bio-
marker in in vivo experiments [10,11]. In this study, we aimed 
to determine the association of arginase activity in tumor tis-
sues and sera with the tumor growth inhibition induced by 
different treatment strategies.
In the present study, 10 kDa interferon γ-induced protein 
(IP-10), a CXC chemokine, was used as an immunotherapeutic 
agent. This chemokine induces antitumor and antimetastatic 
activities in different ways including immunological and anti-
angiogenic mechanisms [12]. We used the murine estrogen-
nonresponsive mammary carcinoma cells, named 4T1 cells, 
which multiply rapidly and cause metastatic tumors in BALB/c 
mice [13]. A comparison of the anti-breast-cancer effects of IP-
10 was performed, when administered either using recombi-
nant naked DNA or delivered via L. tarentolae system, in the 
4T1 mouse tumor model. The level of arginase activity during 
different therapeutic strategies was evaluated to elucidate the 
association between tumor growth and arginase activity.
METHODS
Ethics statement
All mouse experiments including maintenance, animal 
handling, and blood sample collection were approved by the 
Institutional Animal Care and Research Advisory Committee 
of the Pasteur Institute of Iran (Document dated May 2014), 
based on the Specific National Ethical Guidelines for Bio-
chemical Research issued in 2005 by the Research and Tech-
nology Deputy of the Ministry of Health and Medical Educa-
tion (MOHME) of Iran.
Mice and cell lines
Female BALB/c mice, 8-week-old, were purchased from the 
Pasteur Institute of Iran and housed under standard condi-
tions of diet and light in the animal facility. The 4T1 cell line 
(ATCC CRL-2539) was obtained from the Pasteur Institute of 
Iran (National Cell Bank of Iran). The 4T1 and COS-7 cells 
were cultured in RPMI-1640 medium (Sigma, St. Louis, USA) 
supplemented with 10% heat-inactivated fetal bovine serum 
(FBS; Gibco, Waltham, USA), 2 mM L-glutamine (Sigma) 
and 50 µg/mL gentamicin (Biosera, Boussens, France) in a 
humidified atmosphere with 5% CO2 at 37°C. Subculturing 
was carried out every 2 to 3 days. The cells were detached by 
using a solution containing 0.25% trypsin and 1 mM EDTA 
(Sigma).
Plasmid DNA construction
The plasmid pEGFP-N1-(IP-10) constructed in our previ-
ous study was digested [14] with EcoRI and KpnI (all the en-
zymes purchased from Roche, Basel, Switzerland), gel purified 
and sub-cloned into pEGFP-N3. After pEGFP-N3-(IP-10) 
confirmation by polymerase chain reaction (PCR) using IP-
10 forward 5´ -CCA AGT GCT GCC GTC ATT TT-3´  and 
EGFP reverse 5´ -GCTCTAGATTAGGTACCCTTGTA-
CAGCTCGTC-3´  primers and digestion with EcoRI/KpnI, the 
fused (IP-10-egfp) fragment was sub-cloned into BglII/NotI 
sites of the Leishmania expression vector pLEXSY-neo2 (Jena 
Bioscience, Hannover, Germany) for gene transfection. To 
construct pcDNA-(IP-10-egfp), pLEXSY.neo2-(IP-10-egfp) was 
digested with BglII/NotI and then cloned into the correspond-
ing site of pcDNA 3.1+. The plasmid encoding (IP-10-egfp) 
was transformed into DH5α strain of Escherichia coli and then 
purified by the alkaline lysis method (Qiagen Plasmid Giga 
Kit, Dusseldorf, Germany).
Fluorescence microscopy and flow cytometry analysis 
To confirm the expression of pcDNA-(IP-10-egfp) in mam-
malian cells, COS-7 cells were transfected with pcDNA-(IP-
10-egfp) using Polyethylenimine/DNA (PEI/DNA) complexes, 
which were generated by mixing 10 μM linear PEI with 5 μg 
of each DNA (pcDNA-(IP-10-egfp), pEGFP-N3 or pcDNA-
egfp as controls) according to the method described previous-
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ly [15]. The level of EGFP expression in each construct was 
evaluated by fluorescence microscopy (E200; Nikon, Tokyo, 
Japan), flow cytometry (BD Biosciences, Franklin Lakes, USA; 
excitation and emission peaks at 490 nm and 530 nm), and 
Western blot 48 hours after transfection.
Western blot analysis 
To examine the expression of IP-10-egfp protein, Western 
blot analysis was performed [16]. Promastigote forms of 
L. tarentolae-EGFP (~1× 105 parasites) were harvested by cen-
trifugation at 3,000 rpm for 15 minutes and washed in phos-
phate buffered saline (PBS). pcDNA-(IP-10-egfp)- and pEG-
FP-(IP-10-egfp)-transfected COS-7 cells were trypsinized and 
harvested by pipetting gently. The pellets were immediately 
lysed in 2× sodium dodecyl sulfate polyacrylamide gel elec-
trophoresis (SDS-PAGE) sample buffer (4.5 mM Tris-HCl, 
pH 6.8, 10% v/v glycerol, 2% w/v SDS, 5% v/v 2-mercaptoeth-
anol, 0.05% w/v bromophenol blue) on ice and then boiled for 
5 minutes. Cell lysates were separated on 17.5% SDS-PAGE 
gel and transferred onto Protran nitrocellulose transfer mem-
brane (Schleicher and Schuell Bioscience, Dassel, Germany) 
using a wet blotting system (Bio-Rad, Hercules, USA). The 
membrane pre-equilibration was performed overnight using 
Tris-Buffered Saline with Tween-20 (TBST) solution (10 mM 
Tris-HCl, pH 7.4, 150 mM NaCl, and 0.1% Tween-20) con-
taining 2.5% bovine serum albumin (BSA). The membrane 
was then washed three times with 0.1% Tween-20 in TBS. 
Subsequently, the membrane was incubated with monoclonal 
anti-EGFP-HRP Goat antibody diluted to a concentration of 
1:6,000 (Acris Antibodies GmbH, Herford, Germany) for 2 
hours. Finally, the target protein was visualized by developing 
the blot using 3, 3-diaminobenzidine tetrahydrochloride 
(DAB; Sigma) as a peroxidase substrate.
Quantitative real-time PCR analysis
Total RNA was extracted from the transfected COS-7 cells 
3 days after transfection, using the RNeasy Qiagen kit accord-
ing to the manufacturer’s instructions. The quality of the RNA 
was assessed by spectrophotometric analysis using NanoDrop 
ND-1000. Then, 1 µg of total RNA of each sample was reverse 
transcribed to cDNA using the Omniscript RT kit (Qiagen). 
The QuantiNova SYBR Green PCR Kit was used to amplify 
the genes for IP-10 and glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) (normalization control for quantitative 
real-time PCR [qRT-PCR]). The following primers were used 
for qRT-PCR: IP-10 forward primer, IP-10 reverse primer 5´ -
AGG CTC GCA GGG ATG ATT TC-3´ ; GAPDH forward 
primer 5´ -CGA GAG TCA GCC GCA TTT TC-3´ , GAPDH 
reverse primer 5´ -GAT GAC GAG CTT CCC GTT CT-3´ . 
The PCR conditions were as follows: initial denaturation at 
95°C for 1 minute, followed by 40 cycles consisting of dena-
turation at 95°C for 15 seconds and annealing extension at 
60°C for 30 seconds. The absorbance value was measured at 
the extension stage. The 2-ΔΔCt method was applied to calculate 
the IP-10 mRNA relative expression level.
NO assay
Nitrite release in the culture supernatant of the transfected 
COS-7 cells was determined at 6, 24, 48, 72, and 96 hours af-
ter transfection. 100 µL of COS-7 culture supernatant was col-
lected from each well and mixed with an equal volume of 
Griess reagent. Absorbance of colored complex was deter-
mined at 550 nm using a microplate reader. Nitrite concentra-
tion in samples was calculated based on the standard curve 
plotted for sodium nitrate serial dilution in culture medium. 
The amount of induced NO in the transfected COS-7 cells 
was calculated by subtracting, the amount of NO produced in 
untransfected COS-7 cells from total NO amount of different 
samples.
Parasite growth and transfections
The L. tarentolae Tar II (ATCC 30267) strain was grown at 
26°C in M199 medium (Sigma), pH 7.2, supplemented with 
5% heat-inactivated FBS (Gibco), 40 mM hydroxyethyl piper-
azineethanesulfonic acid (HEPES), 0.1 mM adenosine, 5 µg/
mL hemin (all chemicals procured from Sigma), and 50 µg/
mL gentamicin (Biosera). In order to perform homologous 
recombination of a cassette containing IP-10-egfp into the 
Leishmania chromosome, pLEXSY-neo-2-(IP-10-egfp) was lin-
earized using SwaI. For transfection, 4× 107 log-phase para-
sites were washed and resuspended in 300 µL of electropora-
tion buffer (21 mM HEPES, 137 mM NaCl, 5 mM KCl, 0.7 
mM Na2HPO4, and 6 mM glucose; pH 7.5), and mixed with 
50 µL H2O containing 15 µg of cassette containing IP-10-egfp. 
The mixture was stored on ice for 10 minutes, and then elec-
troporated (Bio-Rad Gene PulserEcell) at 450 V and 500 µF as 
described previously [17]. G418 antibiotic (Sigma) was used 
for the selection of recombinant transfectants. In brief, the 
electroporated promastigotes were incubated for 24 hours in 
M199 10% medium at 26°C without any selection drug and 
then plated on solid media (2% noble agar and 10% v/v 2×  
M199; Sigma) containing 50 µg/mL G418 (Gibco). The 
growth of G418-resistant cells was observed after 7 to 10 days. 
The selected clones were further propagated in liquid M199 
medium containing 10% FBS, and in the absence of G418. 
The expression levels of EGFP in Leishmania promastigotes 
were evaluated by epi-fluorescence microscopy for up to 3 
months (Nikon, E 200, ACT-1 software, Digital sight Camera).
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Extraction of genomic DNA and PCR confirmation of IP-10-
egfp gene integration
The genomic DNA of recombinant L. tarentolae strains was 
extracted by GF-1 genomic DNA extraction kit (Vivantis, 
Selangor DE, Malaysia). Integration of the expression cassette 
into the ssu locus was confirmed by diagnostic PCR using ssu 
forward primer (F3001, 5´ -GATCTGGTTGATTCTGCCAG-
TAG-3´ ) and apart reverse primer (A1715, 5´ -TATTCGTT-
GTCAGATGGCGCAC-3´ ). The PCR conditions were as fol-
lows: 95°C for 5 minutes, 60°C for 2 minutes, 72°C for 3 min-
utes, followed by 30 cycles of 94°C for 1 minute, 60°C for 1 
minute and 72°C for 15 minutes, and finally, 1 cycle of 72°C 
for 15 minutes according to the pLEXSY Kit protocol (Jena 
Bioscience).
The presence of IP-10-egfp fusion was confirmed by PCR 
analysis using IP-10 forward primer (5´ -CAGAATTCAT-
CAGCACCATGAACCCAA-3´ ) including EcoRI restriction 
site (underlined), and EGFP reverse primer (5´ -GCTCTAG-
ATTAGGTACCCTTGTACAGCTCGTC-3´ ) including EcoRI 
and XbaI site (underlined), respectively. The PCR was carried 
out under the following conditions: 95°C for 2 minutes (initial 
denaturation); 58°C for 1 minute, 72°C for 3 minutes, 95°C 
for 30 seconds, 58°C for 30 seconds (annealing); 72°C for 1 
minute (extension), for a total of 30 cycles.
PCR for amplification of egfp fragment was carried out us-
ing EGFP forward primer (5´ -ATGATATCAAGATCTATG-
GTGAGCAAGGGC-3´ ), (BglII restriction site indicated in 
bold) and EGFP reverse primer. The reaction mixture was in-
cubated at 94°C for 5 minutes, followed by 30 cycles consist-
ing of 1 minute at 94°C, 2 minutes at 62°C, 1 minute at 72°C, 
and a final extension of 10 minutes at 72°C. The gene amplifi-
cation was done as described earlier [17].
RNA extraction and reverse transcription PCR
RNA was extracted from the recombinant promastigotes 
and used for cDNA synthesis. To detect the presence of egfp 
and IP-10-egfp, PCR was performed using transgenic cDNA 
as template and EGFPF/EGFPR and IP-10F/EGFPR primer 
pairs, respectively.
Immunization schedules 
Mice were divided into five groups of 10 female BALB/c, 
and 1× 105 4T1 cells/100 µL PBS were injected subcutaneously 
in the fourth mammary gland. The mice then received 50 μg 
of pcDNA-(IP-10-egfp) (G1), 2 × 107 parasite/50 µL PBS 
L. tarentolae-(IP-10-EGFP) (G2) and L. tarentolae–EGFP (G3), 
50 μg of pcDNA-egfp (G4), and PBS (G5), twice a week for 3 
weeks. All groups were injected intratumorally. Blood samples 
were collected from 4 mice before 4T1 injection (N, normal), 
3 days after 4T1 injection (G0, 4T1), and 23 days after 4T1 in-
jection (G1–G5). The smallest (a) and the biggest (b) diame-
ters of the tumors were measured using caliper, twice a week. 
The tumor volume was calculated using a previously described 
formula: V= (a2 ·b)⁄2 [14].
Histopathological studies
Lung tissues of 4 mice from each group were collected at 
day 28 and fixed in Bouin’s fixative for 24 hours. After stan-
dard processing and embedding in paraffin blocks, the tissues 
were sliced into 3-micron sections from each paraffin block 
and mounted on slides. Hematoxylin and eosin (H&E) stain-
ing was carried out for histological examination. The stained 
slides were examined under a Nikon eclipse E200 microscope 
and photographed using a Nikon DS-Fi1 camera. The slides 
were assessed for the presence of alveolar edema, hemorrhage, 
and metastatic areas by a pathologist who was not aware of 
the treatment schedule of the different groups. 
Sample preparation for arginase assay
The tumor samples were obtained from sacrificed mice, 28 
days after 4T1 inoculation. The samples were homogenized in 
a 1.5 mL vial containing phosphate-buffered saline 1×  (PBS 
1× ) using a plastic homogenizer. The homogenates were cen-
trifuged at 1,600 rpm for 5 minutes (Eppendorf, Hamburg, 
Germany) at 4°C. The supernatants were centrifuged at 14,000 
rpm for 10 minutes at 4°C and stored at -70°C until further 
use for arginase activity measurement. Serum was separated 
from blood and kept at -70°C prior to the measurement of ar-
ginase activity. The sera samples for determination of arginase 
activity were also collected from mice before injection of 4T1 
(N, normal sera), 3 days after injection of 4T1, before starting 
treatments (G0, 4T1), and 23 days after treatments (G1–G5).
Determination of arginase activity
The protein content of each tumor sample (25 μL) was mea-
sured by BCA protein assay (Thermo Scientific Pierce Chemi-
cal Co., Waltham, USA) using serially diluted BSA as the 
standard. The enzymatic activity of arginase in the tumor was 
determined as described previously [18]. The tumor extract 
(25 μL) was lysed using lysis buffer (0.1% triton X-100, 10 
mM MnCl2, and 50 mM Tris-HCl, pH 7.5) and activated by 
heating at 56°C for 10 minutes. Then 25 μL arginine was add-
ed and the mixture was incubated at 37°C for 1 hour to allow 
complete arginine hydrolysis. The assay was stopped by the 
addition of 400 μL acid mixture containing H2SO4, H3PO4, 
and H2O (1:3:7 v/v). Then 20 μL of 6% isonitrosopropiophe-
none (ISPF; Sigma), dissolved in absolute ethanol, was added 
and the samples were incubated at 100°C for 45 minutes. The 
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absorbance of the urea formed was measured at 540 nm using 
a spectrophotometer (Power Wave XS; Bio-Tek, Winooski, 
USA). One unit of enzyme activity is defined as the amount of 
enzyme that catalyzes the formation of 1 μmol of urea per mg 
of protein. For sera samples, the urea concentrations were de-
termined without performing the activation and hydrolysis 
steps. 
Statistical analysis 
Statistical analysis was performed using Graph-Pad Prism 
5.0 for Windows (Graph-Pad Prism, San Diego, USA). One-
way ANOVA was performed to analyze the arginase assay in 
tumor and sera, and for analyzing the tumor weight and 
spleen weight in different groups. All p-values less than 0.05 
were considered statistically significant. Data were demon-
strated as mean± standard deviation.
RESULTS
Construction of recombinant L. tarentolae expressing IP-10-
EGFP
The linearized pLEXSY-(IP-10-egfp) was introduced into 
18S rRNA ssu locus of L. tarentolae by electroporation (Figure 
1A). Successful insertion of IP-10-egfp into the L. tarentolae ge-
nome was further verified by performing PCR using L. tarentolae 
genome as template and L. tarentolae-EGFP genome as a con-
trol, and visualizing the PCR products of expected size. The 
integration of IP-10-egfp expression cassette into the ssu locus 
was confirmed by PCR analysis using genomic recombinant 
L. tarentolae as template that yielded a 1 kb fragment (Figure 
1B). Furthermore, obtaining the PCR products of expected 
size, using L. tarentolae-(IP-10-EGFP) cDNA and the specific 
primers, confirmed the expression of IP-10-EGFP fusion gene 
in transgenic L. tarentolae (Figure 1C). As shown in Figure 1D, 
EGFP expression in G418-resistant transgenic L. tarentolae 
was confirmed by fluorescence microscopy. 
In vitro expression of IP-10 EGFP in COS-7 transfected cells
To analyze and confirm the in vitro expression of IP-10 un-
der the control of a cytomegalovirus (CMV) promoter in 
eukaryotic cells, COS-7 cells were transfected with pcDNA-
(IP-10-egfp) and pEGFP-(IP-10) constructs and then exam-
ined using fluorescence microscopy as well as fluorescence-
activated cell sorting (FACS) (Figure 2A, B). The transfection 
efficacies of pcDNA-(IP-10-egfp) and pEGFP-(IP-10) were al-
most similar with regard to EGFP-positive cell percentage as 
detected by flow cytometry (Figure 2B). However, the mean 
fluorescent intensities of COS-7 cells transfected with pcDNA-
(IP-10-egfp) (17.6%) and pEGFP-(IP-10) (19.2%) were lower 
compared to the pEGFP-transfected COS-7 cells. This reduc-
tion might have possibly occurred due to the presence of IP-
10 along with the egfp gene. 
Figure 1. Interferon γ-induced protein 10-enhanced green fluorescent protein (IP-10-EGFP) integration and expression in Leishmania tarentolae strain. 
(A) Schematic presentation of egfp gene into ssu ribosomal DNA lucus. (B) Polymerase chain reaction (PCR) results using L. tarentolae genomic DNA 
as template. Columns 1 and 2 demonstrate the IP-10-EGFP and EGFP amplification, respectively. Column 3 is the PCR amplification of the integrated 
fragment using integration primers (F3001 and A1715) primers. (C) Confirmation of IP-10-EGFP expression in mRNA level. Amplification of IP-10-EGFP 
and EGFP fragments were demonstrated in column 1 and 2 using recombinant L. tarentolae cDNA as template, respectively. (D) Fluorescence micro-
scopic images of recombinant L. tarentolae stably expressing (IP-10-EGFP) 48 hours postinfection; both bright field and fluorescence (left) are shown.
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Figure 2. Confirmation of interferon γ-induced protein 10 (IP-10) expression in COS-7 transfected cells. (A) GFP expression was assessed by fluores-
cence microscopy after 48 hours. (a) Untreated COS-7, (b) COS-7 treated with pEGFP, (c) COS-7 treated with pEGFP-(IP-10), and (d) COS-7 treated 
with pcDNA-(IP-10-egfp). (B) GFP positive percentage of transfected parasite by flowcytometer after 48 hours. (e) Untreated COS-7, (f) COS-7 treated 
with pEGFP, (g) COS-7 treated with pcDNA-(IP-10-egfp), and (h) COS-7 treated with pEGP-IP-10. (C) Western blot analysis using anti-GFP antibody. 
Column 1 and 2 show marker and untreated COS-7 as negative control, respectively. The ~27 kDa band determines the GFP protein expression in 
Leishmania tarentolae-EGFP as positive control (column 3) and pEGFP-transfected COS-7 cells (column 4). IP-10-EGFP expression was confirmed 
by detecting ~37 kDa in pcDNA-(IP-10-egfp) (column 5) and pEGFP-(IP-10-EGFP) treated COS-7 cells (column 6).
GFP=green fluorescent protein; EGFP=enhanced green fluorescent protein; R1=COS-7 cells; RN1=GFP positive COS-7; FL1=fluorescein isothio-
cyanate (FITC) detector.
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Figure 3. Quantitative real-time polymerase chain reaction (qRT-PCR) 
analysis of interferon γ-induced protein 10 (IP-10) expression in pcDNA-
(IP-10-egfp)-transfected COS-7 cells. qRT-PCR were performed 72 
hours after transfection of pcDNA-egfp and pcDNA-(IP-10-egfp) into 
COS-7 cells. Data are presented as mean±SD (n=4).
EGFP=enhanced green fluorescent protein. 
*p<0.05.
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Figure 4. Effect of interferon γ-induced protein 10 (IP-10) on nitric oxide 
production. The supernatant of pcDNA-egfp and pcDNA-(IP-10-egfp)-
transfected COS-7 cells were collected 6, 24, 48, 72, and 96 hours after 
transfection. Nitrate in the supernatant were measured with Griess reac-
tion. Data are presented as mean±SD (n=4). 
EGFP=enhanced green fluorescent protein. 
*p<0.05.
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Figure 5. The effect of different therapeutic strategy on 4T1 tumor growth, spleen growth and lung histological sections. (A) Schematic representation of 
the immunotherapy schedule. BALB/c mice (n=10) were injected subcutaneously with 1×105 4T1 cells. Different immunization regimes were given in-
tratumorally twice a week for 3 weeks. (B) Tumor volumes were determined two times per week. (C) Tumors were sectioned at day 28 and weight was 
measured among the five groups. (D) Spleens also were sectioned and weighted. Data are presented as mean±SD (n=4). (E) At day 28 lungs were re-
moved, sectioned and stained with H&E. (1) Normal alveolar cavity with normal respiratory bronchioles (black arrowhead) and no significant pathologic 
changes in pcDNA-(IP-10-egfp) (G1). Alveolar septa have normal thickness with no congestion, edema or inflammation. (2) Hemorrhagic lung tissue in L. 
tarentolae-(IP-10-GFP) (G3) with diffused alveolar edema fluid in alveolar spaces (arrow). Alveolar septa show congestion. (3) One foci of metastatic car-
cinoma cells in field (white arrowhead) in G5. Arrow head shows sheet of metastatic carcinoma which encircle a respiratory bronchiole. The tumoral 
cells have high nuclear/cytoplasmic ratio, vascular pleomorphic nuclei and prominent nucleoli (H&E stain, ×100). 
IP-10-GFP=interferon γ-induced protein 10-green fluorescent protein; L. tar=Leishmania tarentolae; PBS=phosphate buffered saline. 
*p<0.05; †p<0.001; ‡p<0.0001.
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Identification and verification of IP-10 protein
For evaluating the expression levels of IP-10-EGFP protein, 
western blot analysis was performed using anti-EGFP anti-
body. The expected band at approximately 27 kDa (Figure 2C) 
was detected in both L. tarentolae-EGFP and pEGFP-trans-
fected COS-7 cell lysate; however, no specific band was ob-
served in the nontransfected COS-7 cells (negative control). 
As the molecular weights of IP-10 and EGFP are 10 kDa and 
27 kDa, respectively, the expressed IP-10-EGFP has a molecu-
lar weight of approximately 37 kDa (Figure 2C) as detected in 
COS-7 cell lysate transfected with pEGFP-(IP-10) and pcDNA-
(IP-10-egfp). These results demonstrated the expression of 
IP-10-egfp integrated into the 18S rRNA locus of transgenic 
L. tarentolae.
Quantification of IP-10 expression in pcDNA-(IP-10-egfp)-
transfected COS-7 cells 
The 2-ΔΔ CT method was applied to quantify the IP-10 ex-
pression in the pcDNA-(IP-10-egfp)-transfected COS-7 cells 
relative to the pcDNA-egfp transfected COS-7 cells. IP-10 ex-
pression was significantly increased (18-fold) in the pcDNA-
(IP-10-egfp)-transfected COS-7 cells as compared with the 
pcDNA-egfp-transfected COS-7 cells, 72 hours after transfec-
tion (Figure 3).
NO induction in pcDNA-(IP-10-egfp)-transfected COS-7 cells
Higher amounts of NO were produced in the pcDNA-(IP-
10-egfp)-transfected COS-7 cells compared with that in the 
pcDNA-egfp-transfected COS-7 cells at all time points (Figure 
4). The levels of NO were significantly high at 72 hours after 
transfection (p< 0.05). 
Effect of pcDNA-(IP-10-egfp) on tumor growth, tumor weight, 
and spleen weight 
Mice were sacrificed 28 days after 4T1 inoculation and the 
weight of isolated tumors and spleens was determined at the 
time of sacrifice (Figure 5A). The efficacy of the various im-
munotherapy regimens in eliciting therapeutic responses 
against 4T1 was evaluated by measuring the tumor size (Figure 
5B). Twenty-eight days after 4T1 inoculation, four mice from 
each group (G1–G5) were sacrificed, and tumors and spleens 
were collected and weighed. As shown in Figure 5B, there is a 
significant difference in the tumor growth between the pcD-
NA-(IP-10-egfp) (G1) and PBS groups (p< 0.01), 17 days after 
4T1 inoculation. The average tumor volume in the PBS group 
was approximately 498.7 mm3, in contrast to the tumor vol-
ume in the pcDNA-(IP-10-egfp) treated mice, which was only 
92.8 mm3. The ability of IP-10 encoding DNA plasmid to re-
duce tumor growth was further confirmed by the significant 
difference observed in the tumor weight between the pcDNA-
(IP-10-egfp) (G1) and PBS groups, 28 days after 4T1 injection. 
Furthermore, the tumor weight in L. tarentolae-(IP-10-EGFP)-
immunized mice (G3) was significantly decreased in compari-
son to the PBS group (p< 0.05) (Figure 5C).
Regarding the spleen weight, the pcDNA-(IP-10-egfp) group 
demonstrated the best treatment results. The pcDNA-(IP-
Figure 6. Arginase activity in tumor tissues and sera. Different immunization regimens were given to BALB/c mice (n=10) twice a week for 3 weeks, 3 
days after 4T1 injection. (A) Arginase activity of different groups was measured in sera samples before 4T1 injection (N, normal), 3 days after injection 
4T1 (G0, 4T1) and 23 days after injection of 4T1 (G1–G5). (B) Arginase activity in different groups was determined in tumor tissues 28 days after 4T1 in-
jection. Data are representative of mean±SD (n=4).
IP-10-GFP=interferon γ-induced protein 10-green fluorescent protein; L. tar=Leishmania tarentolae; PBS=phosphate buffered saline. 
*p<0.05.
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10-egfp)-immunized mice showed a significant difference in 
the spleen weight compared with L. tarentolae-(IP-10-EGFP) 
group (p < 0.01) (Figure 5D). These results suggested that 
pcDNA-(IP-10-egfp) has the ability to effectively protect mice 
from metastasis of breast cancer to spleen.
Histopathological studies in mice
Four mice from all groups were sacrificed at day 28 to col-
lect the lung tissues for histopathological analysis. Normal al-
veolar spaces and bronchioles were seen in the lung tissue of 
the pcDNA-(IP-10-egfp) group (G1) as displayed in Figure 5E. 
In contrast, L. tarentolae-(IP-10-egfp) immunotherapy (G3) 
caused diffused alveolar edema, hemorrhage, and congestion 
of alveolar septae. In the PBS group (Figure 5E), foci of meta-
static carcinoma in the lung tissue and a sheet of metastatic 
breast cancer cells encircling a respiratory bronchiole were 
observed.
Levels of arginase activity in isolated tumors and sera
We found that the arginase activity in the sera samples of 
the pcDNA-(IP-10-egfp) group was similar to the normal 
sera (Figure 6A). The mice injected with pcDNA-egfp also 
had the same level of arginase activity as the pcDNA-(IP-
10-egfp) group. L. tarentolae-(IP-10-EGFP), L. tarentolae-
EGFP and PBS groups also showed similar levels of arginase 
activity with no significant differences observed between the 
groups (Figure 6A).
The level of arginase activity in the tumor samples of the 
mice was investigated 28 days after 4T1 inoculation. As shown 
in Figure 6B, there was significantly higher arginase activity in 
tumor samples compared to normal tissue (G4 and G5 vs. 
normal mice, p< 0.05). However, no significant difference was 
observed among the tumor samples from each group. There-
fore, the level of arginase activity could be used to differentiate 
between tumor tissue and normal tissue. 
DISCUSSION
The objective of this study was to construct a recombinant 
L. tarentolae strain stably expressing IP-10, and to evaluate its 
potential as a candidate live vaccine against 4T1-induced 
breast cancer. We employed the arginase assay as a biomarker 
to identify the more efficient therapeutic strategy., The appli-
cation of L. tarentolae as a live vector to deliver therapeutic 
agent in breast cancer model was reported for the first time in 
this study. 
For generating recombinant L. tarentolae, the pLEXSY-neo2 
system was used to integrate the IP-10 encoding plasmid into 
the parasite genome. IP-10 integration into L. tarentolae and 
subsequent expression was confirmed by different methods 
including PCR, fluorescence imaging, FACS and western blot 
analysis. In this study, two immunotherapeutic approaches 
including L. tarentolae live delivery system and naked DNA 
plasmid were compared for the treatment of the 4T1-implant-
ed BALB/c mice with IP-10-EGFP. 
To confirm the expression of IP-10 in eukaryotic cells, qRT-
PCR analysis and NO assay were performed in the pcDNA-(IP-
10-egfp)-transfected COS-7 cells. Gupta et al. [19] have previ-
ously reported that the protective effect of IP-10 is mediated by 
the induction of inducible NO synthase 2 and subsequent pro-
duction of NO. In this study, the NO induction in pcDNA-(IP-
10-egfp)-transfected COS-7 cells revealed the functional ex-
pression of IP-10 that mediated the protective effect.
This study demonstrated that IP-10 is a promising candi-
date for the treatment of breast cancer, as evident from the ex-
periments carried out in the in 4T1 mouse tumor model. This 
observation is supported by the results of Yang et al. [20], who 
demonstrated that IP-10 has the ability to chemo-attract tu-
mor-specific T-cells to the tumor site and also to promote the 
proliferation of these recruited T-cells leading to tumor re-
gression in mice harboring 4T1 cells. Our results demonstrat-
ed that pcDNA-(IP-10-egfp) can inhibit tumor growth as well 
as tumor metastasis to spleen in 4T1-implanted mice when 
compared to the L. tarentolae-(IP-10-EGFP) and control 
groups. Xanthopoulos et al. [21] mentioned that spleen size is 
a good marker for indicating the degrees of 4T1 metastasis to 
spleen in treated mice. The histological examination of the 
lungs demonstrated that pcDNA-(IP-10-egfp) has the ability to 
reduce lung metastasis. Similar results have been reported for 
melanoma and ovarian cancer [22].
Different delivery systems such as cationic liposomes [23], 
have been used in different studies to transfer IP-10 gene to 
the target organs. In this study, a live vector was used for IP-10 
delivery. Such a system has several advantages including low 
cost of preparation, strong immune stimulation, and is well-
tolerated in human [5]. L. tarentolae is a nonpathogenic para-
site, which lives for 2 to 3 days in mammalian cells. It can acti-
vate the dendritic cell maturation process, induce T-cell pro-
liferation, and the production of gamma-interferon, thus 
leading CD4+ T-cells to develop a Th1 phenotype [24]. There-
fore, we assumed that L. tarentolae has the ability to deliver our 
therapeutic candidate to tumor cells. It was found that 
L. tarentolae like Listeria is eliminated by the immune system 
after 3 to 4 days in normal tissues [25]. Therefore, to establish 
a longer presence of L. tarentolae-(IP-10-EGFP) in tumor cells 
frequent intratumoral injections of L. tarentolae-(IP-10-EGFP) 
(six times in 3 weeks) was administered. Surprisingly, 
L. tarentolae-(IP-10-EGFP) treated mice showed higher tumor 
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weight, tumor growth, and spleen weight (even higher than 
PBS group) and higher arginase activity in sera in comparison 
with the group immunized with pcDNA-(IP-10-egfp). How-
ever, our group has shown that a single intraperitoneal injec-
tion of recombinant L. tarentolae expressing A2 induced high 
levels of IFN-γ against visceral leishmaniasis in a preventive 
approach [26]. In another study conducted for preventive ap-
proach, all groups were challenged 3 weeks after the booster 
dose [7]. Breton et al. [6] similarly utilized the single immuni-
zation regimen with recombinant L. tarentolae, followed by in-
fective HIV-1 challenge at a later time-point. As far as we 
know, this study is the first to report the use of L. tarentolae in 
a therapeutic approach. Consistent with our results, Chandra 
et al. [25] demonstrated that Listeria has little effect on prima-
ry tumors (tumor weight) in semi-therapeutic approaches. 
However, these live bacteria, when used in an optimized pro-
tocol, have the ability to reduce the number of metastases. A 
regimen comprising 5 immunizations with a lower dose of 
bacteria (1× 104) on alternate days was more effective against 
the metastases than 3 higher doses (0.5× 107) administered 
once a week. Overall, it can be surmised that the ineffective-
ness of L. tarentolae in our study might be due to the inability 
of the mouse immune system to kill all tumor cells in the pri-
mary tumors after six injections of L. tarentolae-(IP-10-EGFP).
In recent years, increasing attention has been focused on ar-
ginase as a potential therapeutic target. It has been shown that 
these isoenzymes are overexpressed in multiple distant organs 
and tissues of patients [27]. Furthermore, several cancer stud-
ies have shown the crucial role of arginase in tumor immuno-
biology [10]. Meanwhile, there are some studies that have re-
ported higher levels of arginase and polyamines (arginase 
products) in the sera and tissues of breast cancer patients [28]. 
Increased arginase activity probably causes damage to the 
host’s immune response [29]. In our study, the arginase activi-
ty in the tissues of normal mice was significantly lower than in 
the therapeutic and control groups (Figure 6B). L. tarentolae-
(IP-10-EGFP) group had the lowest arginase activity but did 
not show any significant differences when compared to other 
groups. Overall, it can be concluded that arginase activity in 
tumor tissues cannot differentiate between the efficacies of 
different therapeutic regimens. However, the sterol fraction of 
Porphyra dentata caused a significant decrease in the arginase 
activity in MDSCs in 4T1 tumor-cell-engrafted mice in vivo 
[30]. Herein, it was revealed that determination of arginase 
activity in tumor tissues without MDSCs sorting is not effec-
tive in discriminating between different therapeutic strategies.
Our results indicate that IP-10 is a promising candidate for 
treatment of breast cancer, as demonstrated in the 4T1-im-
planted BALB/c mouse tumor model. However, dose modifi-
cations are required for the L. tarentolae-(IP-10-EGFP) live de-
livery system to be effective in the regimen used in this study 
(six injections in 3 weeks). Furthermore, to improve the effica-
cy of L. tarentolae-based cancer immunotherapy, addition of 
tumor associated antigens or agents that reduce immune sup-
pression is strongly suggested. We found that the arginase as-
say in tumor tissues can be a good biomarker for distinguish-
ing tumor tissues from the normal ones. To successfully dis-
tinguish treated samples from the untreated ones, determining 
arginase activity in MDSCs is highly recommended.
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